Auro Laboratories Limited
BSE: AUROLAB
Prev Close
253.5
Open Price
253.5
Volume
3,778
Today Low / High
245.1 / 260
52 WK Low / High
170 / 292.8
Range
238 - 263
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 250.05, reflecting a change of -3.45 (-1.36095%). The expected target range on the BSE is 238 - 263. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.
Auro Laboratories Limited Graph
Auro Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Auro Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 250.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 250.05 | 252.55 | 227.30 - 277.81 |
| 255.05 | 204.04 - 306.06 | ||
| 257.55 | 180.29 - 334.82 | ||
| Bearish Scenario | 250.05 | 247.55 | 222.79 - 272.30 |
| 245.05 | 196.04 - 294.06 | ||
| 242.55 | 169.78 - 315.31 |
Overview of Auro Laboratories Limited
ISIN
INE292C01011
Industry
Medical - Pharmaceuticals
Vol.Avg
6,503
Market Cap
1,558,436,625
Last Dividend
0
Official Website
IPO Date
2000-11-13
DCF Diff
362.39
DCF
-112
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 52.70 Cr | 27.76 Cr | 24.94 Cr | 0.4732 | 0.00 Cr | 0.88 Cr | 9.58 Cr | 7.79 Cr | 12.50 | 10.67 Cr | 0.1479 |
| 2023-03-31 | 52.26 Cr | 36.73 Cr | 15.54 Cr | 0.2973 | 0.00 Cr | 0.39 Cr | 4.26 Cr | 2.44 Cr | 3.92 | 4.39 Cr | 0.0467 |
| 2022-03-31 | 50.44 Cr | 33.58 Cr | 16.86 Cr | 0.3342 | 0.00 Cr | 0.35 Cr | 4.65 Cr | 2.84 Cr | 4.56 | 5.72 Cr | 0.0564 |
| 2021-03-31 | 52.93 Cr | 29.84 Cr | 23.10 Cr | 0.4364 | 0.00 Cr | 0.32 Cr | 10.96 Cr | 7.18 Cr | 11.52 | 12.00 Cr | 0.1356 |
| 2020-03-31 | 42.90 Cr | 25.57 Cr | 17.33 Cr | 0.4040 | 0.00 Cr | 0.43 Cr | 6.17 Cr | 4.05 Cr | 6.51 | 7.24 Cr | 0.0945 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 0.99 Cr | 85.73 Cr | 43.77 Cr | 41.9678 Cr | 26.24 Cr | 25.25 Cr | 8.24 Cr | 54.83 Cr | 0.00 Cr | 0.00 Cr | -0.42 Cr | 23.9345 Cr |
| 2023-03-31 | 1.79 Cr | 55.99 Cr | 21.79 Cr | 34.2004 Cr | 6.41 Cr | 4.63 Cr | 11.76 Cr | 20.28 Cr | 1.06 Cr | 0.00 Cr | -9.67 Cr | 18.1310 Cr |
| 2022-03-31 | 5.21 Cr | 54.96 Cr | 23.44 Cr | 31.5210 Cr | 13.78 Cr | 8.57 Cr | 4.25 Cr | 17.28 Cr | 1.51 Cr | 1.66 Cr | -6.52 Cr | 20.1306 Cr |
| 2021-03-31 | 10.82 Cr | 41.89 Cr | 13.31 Cr | 28.5826 Cr | 3.16 Cr | -7.66 Cr | 2.55 Cr | 13.69 Cr | 1.05 Cr | 2.39 Cr | -2.95 Cr | 9.2357 Cr |
| 2020-03-31 | 2.44 Cr | 32.35 Cr | 10.85 Cr | 21.4976 Cr | 3.16 Cr | 0.71 Cr | 4.06 Cr | 14.35 Cr | 0.00 Cr | 3.16 Cr | 0.05 Cr | 6.1355 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 18.8072 Cr | -38.6702 Cr | 19.0948 Cr | -16.8330 Cr | -0.7682 Cr | 1.6488 Cr | -35.6402 Cr | 10.3457 Cr | 19.8304 Cr | 0.0000 Cr | 3.5161 Cr |
| 2023-03-31 | 3.2812 Cr | -5.0813 Cr | -8.1785 Cr | -0.7930 Cr | -9.9787 Cr | 2.4170 Cr | -4.0742 Cr | 3.4457 Cr | -7.3643 Cr | 0.0000 Cr | -7.5012 Cr |
| 2022-03-31 | -6.5905 Cr | -5.3428 Cr | 9.7926 Cr | -11.2001 Cr | -2.1406 Cr | 12.3957 Cr | -4.6096 Cr | 3.8739 Cr | 10.6190 Cr | 0.0000 Cr | -1.7079 Cr |
| 2021-03-31 | 12.8156 Cr | -3.5079 Cr | -0.4556 Cr | 12.4406 Cr | 8.8522 Cr | 14.5363 Cr | -0.3751 Cr | 10.5054 Cr | 0.0028 Cr | 0.0000 Cr | 1.5159 Cr |
| 2020-03-31 | 9.3004 Cr | -2.2076 Cr | -5.5163 Cr | 8.6281 Cr | 1.5765 Cr | 5.6842 Cr | -0.6723 Cr | 5.6418 Cr | -4.9383 Cr | 0.0000 Cr | -0.6887 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 3.05 Cr | 2.28 Cr | 0.77 Cr | 0.2523 | 0.17 Cr | 0.05 Cr | 0.08 | 0.58 Cr | 0.0167 |
| 2024-09-30 | 3.10 Cr | 0.06 Cr | 3.05 Cr | 0.9820 | 0.45 Cr | 0.36 Cr | 0.57 | 1.03 Cr | 0.1155 |
| 2024-06-30 | 5.72 Cr | 1.74 Cr | 3.98 Cr | 0.6950 | 1.05 Cr | 0.75 Cr | 1.21 | 1.53 Cr | 0.1316 |
| 2024-03-31 | 12.06 Cr | 4.40 Cr | 7.66 Cr | 0.6353 | 2.53 Cr | 2.38 Cr | 3.83 | 2.81 Cr | 0.1975 |
| 2023-12-31 | 17.98 Cr | 9.66 Cr | 8.32 Cr | 0.4628 | 4.23 Cr | 2.73 Cr | 4.39 | 4.50 Cr | 0.1521 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 0.07 Cr | 8.65 Cr | 8.72 Cr | 0.00 Cr | 7.01 Cr | 22.51 Cr | 61.47 Cr | 84.03 Cr | 40.66 Cr |
| 2024-03-31 | 0.99 Cr | 0.00 Cr | 0.99 Cr | 13.39 Cr | 8.24 Cr | 30.39 Cr | 54.83 Cr | 85.27 Cr | 43.77 Cr |
| 2023-12-31 | -6.98 Cr | 13.95 Cr | 6.98 Cr | 0.00 Cr | 0.00 Cr | 6.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 6.35 Cr | 8.99 Cr | 15.34 Cr | 0.00 Cr | 11.07 Cr | 35.72 Cr | 25.94 Cr | 61.71 Cr | 24.69 Cr |
| 2023-06-30 | -1.79 Cr | 3.57 Cr | 1.79 Cr | 0.00 Cr | 0.00 Cr | 1.79 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 2.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-06-30 | 0.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-03-31 | 1.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹820.60 | ₹98,220,756,898.00 | ₹85,846.00 |
Key Executives
Gender: male
Year Born: 1978
Gender: male
Year Born: 1950
Gender: female
Year Born:
Gender: male
Year Born: 1971
FAQs about Auro Laboratories Limited
The CEO is Mr. Sharat Sahadeolal Deorah B.Com..
The current price is ₹250.05.
The range is ₹170-292.8.
The market capitalization is ₹155.84 crores.
The P/E ratio is 44.98.
The company operates in the Healthcare sector.
Overview of Auro Laboratories Limited (ISIN: INE292C01011) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹155.84 crores and an average daily volume of 6,503 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.